Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
JAMA Ophthalmol. Author manuscript; available in PMC 2014 March 1.
Published in final edited form as:
PMCID: PMC3652586

Attenuation of Choroidal Neovascularization by β2-Adrenergic Receptor Antagonism

Jeremy A. Lavine, MD, PhD,1 Yanzhi Sang, MD, PhD,1 Shoujian Wang, MD, PhD,1 Michael S. Ip, MD,1 and Nader Sheibani, PhD1,2,*



To determine if β-adrenergic blockade inhibits choroidal neovascularization (CNV) in a mouse model of laser-induced CNV, and to investigate the mechanism by which β-adrenoreceptor antagonism blunts CNV.


The impact of β-adrenoreceptor blockade on CNV was determined using the laser-induced CNV model. Briefly, mice were subjected to laser burns, inducing CNV, and treated with daily intraperitoneal injections of propranolol. Neovascularization was measured on choroidal-sclera flat mounts using intercellular adhesion molecule-2 immunofluorescence staining. The impact of β-adrenergic receptor signaling on expression of vascular endothelial growth factor (VEGF) was investigated using primary mouse choroidal endothelial cells (ChEC) and retinal pigment epithelial (RPE) cells. These cells were incubated with β-adrenoreceptor agonists and/or antagonists, and assayed for VEGF mRNA and protein levels.


Propranolol-treated mice demonstrated a 50% reduction in laser-induced CNV. Norepinephrine treatment stimulated VEGF mRNA expression and protein secretion in both ChEC and RPE cells. This effect was blocked by β2-adrenoreceptor antagonism and mimicked by β2-adrenergic receptor agonists.

Conclusions and Clinical Relevance

β-Adrenergic blockade attenuated CNV. β2-Adrenergic receptors regulated VEGF expression in ChEC and RPE cells. Antagonists of β-adrenergic receptors are safe and well tolerated in patients with glaucoma and cardiovascular disease. Thus, blockade of β-adrenoreceptors may provide a new avenue to inhibit VEGF expression in CNV.


Exudative age-related macular degeneration (AMD) is one of the leading causes of blindness worldwide1. Exudative AMD develops when vascular tissue from the choriocapillaris invades through a break in Bruch’s membrane into the sub-retinal pigment epithelium (RPE) and/or sub-retinal space; this process is termed choroidal neovascularization (CNV). Leakage of blood, serous fluid, and lipid from CNV causes central vision loss and ultimately leads to an irreversible fibrovascular scar1.

Histopathological studies of CNV membranes have provided valuable insight into the pathogenesis of exudative AMD. Several studies identified choroidal endothelial cells (EC), retinal pigment epithelium (RPE) cells, fibroblasts, myofibroblasts, photoreceptors, glial cells, and macrophages within surgically excised CNV membranes26. Follow up studies focusing upon growth factor expression demonstrated interleukin-1β7, tumor necrosis factor-α7, tissue factor8, monocyte chemotactic protein8, transforming growth factor-β9,10, acidic and basic fibroblast growth factors9,10, platelet-derived growth factor10, and vascular endothelial growth factor (VEGF)68,1013 within these CNV membranes. VEGF expression localized to RPE, choroidal endothelium, fibroblasts, and macrophages 68,1013. Since VEGF is a secreted protein that stimulates vascular permeability and angiogenesis14,15, it was hypothesized to play a central role in CNV.

Experimental models demonstrate a causative role for VEGF in CNV. In the laser-induced model, VEGF is up-regulated in RPE, choroidal endothelium, fibroblasts, and macrophages16. In this same model, inhibition of VEGF signaling prevents CNV17. These studies demonstrate that VEGF is correlated with and necessary for CNV. Overexpression of VEGF in photoreceptors18 and in the RPE19 produces retinal and intrachoroidal neovascularization, respectively, that did not cross Bruch’s membrane. However, adenoviral injection into the sub-retinal space, which both damages Bruch’s membrane and stimulates overexpression of VEGF in the RPE, causes CNV20. These studies demonstrate that a break in Bruch’s membrane and elevated VEGF levels are sufficient for CNV. These studies led to the ANCHOR21 and MARINA22 trials, which established anti-VEGF therapy as the gold standard for treatment of exudative AMD.

Despite the significant breakthrough of anti-VEGF therapy, patients must undergo a large treatment burden, consisting of monthly intravitreal injections. Recently, it was serendipitously discovered that the β-adrenergic receptor blocker propranolol regresses periocular hemangiomas23,24. The putative mechanism for this phenotype is the inhibitory action of β-adrenergic blockers on VEGF production in multiple non-ocular cell types2527, including EC2831. In the retina, propranolol or β2-adrenoreceptor blockade inhibit neovascularization in the oxygen-induced retinopathy (OIR) model via reduced VEGF production32,33. These studies suggest that β-adrenergic receptor blockade could be an alternative or adjunctive anti-VEGF treatment.

To test this hypothesis, we determined if propranolol could suppress CNV in the laser-induced model. Since RPE and ChEC have consistently been shown to be a source of VEGF production in CNV, we established a model of norepinephrine-induced VEGF production in primary mouse RPE and ChEC. We finally investigated which β-adrenergic receptor drives norepinephrine-stimulated VEGF expression.

Materials and Methods


Norepinephrine (10 mM; A7257, Sigma, St. Louis, MO) was dissolved in 0.5 M HCl. β-adrenoreceptor agonists and antagonists propranolol (1 mM; P0884, Sigma), CGP 20712 (1 mM; β1-adrenoreceptor antagonist; #1024, Tocris, R&D Systems, Minneapolis, MN), ICI 118,551 (100 μM; β2-adrenoreceptor antagonist; #0812, Tocris), SR 59230A (100 μM; β3-adrenoreceptor antagonist; #1511, Tocris), xamoterol (100 μM; β1-adrenoreceptor agonist; #0950, Tocris), formoterol (100 μM; β2-adrenoreceptor agonist; #1448, Tocris), and BRL 37344 (1 mM; β3-adrenoreceptor agonist; #0948, Tocris) were dissolved in water.


All research using mouse models of CNV was carried out in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Vision Research and was approved by the Institutional Animal Use and Care Committee of the University of Wisconsin School of Medicine and Public Health. Wild-type 6 week-old female C57BL/6j mice were housed on a 12-hour light-dark cycle and provided with food and water ad libitum. Laser-induced CNV experiments were performed as previously described34. Briefly, mice were anesthetized and treated with 3 focal laser burns in each eye. Propranolol was dissolved in citrate buffer and delivered daily via intraperitoneal injection at 20 mg/kg. After 14 days, mice were sacrificed and CNV was measured on choroidal-sclera flat mounts using intercellular adhesion molecule-2 (ICAM-2; BD BioSciences) immunofluorescence staining. Images were analyzed using ImageJ software.

Preparation of anti-PECAM-1 antibody-coated magnetic beads

Sheep anti-rat Dynabeads (Invitrogen) were washed 3 times with serum-free DMEM (Dulbecco’s Modified Eagle’s Medium, Invitrogen) and then incubated with PECAM-1 antibody (MEC13.3, BD Pharmingen) overnight at 4°C (10 μl beads in 1 mL DMEM). Following incubation, beads were washed 3 times with DMEM containing 10% fetal bovine serum (FBS), re-suspended in the same medium, and stored at 4°C.

Isolation and culture of choroidal endothelial and RPE cells

Eyes from one litter (6 to 10 pups) of 4 week-old immortomice (C57BL/6j) were enucleated and all connective tissue and muscle was removed from the sclera. In cold DMEM, the anterior eye was removed, followed by the lens, vitreous, retina and optic nerve, leaving only a tissue composed of RPE, choroid, and sclera. At this point, ChEC were isolated from the RPE-choroid-sclera complex identically to retinal EC as previously described, using anti-PECAM-1 antibody-coated magnetic beds. ChECs were analyzed by FACS to document purity and grown identically to retinal EC35.

For RPE cells, two sets of tweezers were used to remove the RPE sheet, which was then digested in 5 ml of type I collagenase (1 mg/ml in serum-free DMEM, Worthington) for 45 minutes at 37°C. Following digestion, DMEM with 10% FBS was added and cells were centrifuged at 400 xg for 10 min. The cellular digest was filtered through a double layer of sterile 40 μm nylon mesh (Sefar America Inc., Fisher Scientific), centrifuged, and washed twice with DMEM containing 10% FBS. RPE cells were plated into a single well of a 24 well plate pre-coated with 2 μg/ml of human fibronectin (BD Biosciences, San Jose, CA). To document purity, RPE cells were analyzed by FACS as previously described35 using anti-bestrophin (MAB5466, Millipore, Billerica, MA) and anti-RPE65 (MAB5428, Millipore) antibodies. RPE cells were grown in low glucose DMEM containing 10% FBS, 2 mM L-glutamine, 100 μg/ml streptomycin, 100 U/ml penicillin, and murine recombinant interferon-γ at 44 units/ml.

ChEC and RPE cells were maintained at 33°C with 5% CO2 in 1% gelatin-coated 60 mm dishes. Cells were not allowed to grow beyond 20 passages. Prior to experiments, cells were serum starved overnight in serum-free medium. Serum-free medium was identical to growth medium described above except it lacked 10% FBS, and the ChEC medium also lacked EC growth supplement.

VEGF Analysis

For mRNA analysis, cells were pre-incubated for 30 minutes and/or incubated for 2 hours in 24 well plates. Cells were then washed with 1X PBS, lysed in RLT plus, and frozen at −20°C. mRNA was extracted using RNeasy Plus Mini Kit (Qiagen, Valencia, CA). The cDNA was synthesized using Sprint RT Complete-Double PrePrimed (Clontech, Mountain View, CA). VEGF mRNA was measured by quantitative PCR (Eppendorf, Hauppauge, NY) and normalized to the housekeeping gene RpL13A by generating a ΔCt value. Fold values were generated by normalizing to the vehicle control. Vehicle control samples were used to assay for baseline levels of VEGF and β-adrenergic receptors. For VEGF secreted protein analysis, cells were incubated for 24 hours in 12 well plates. VEGF levels were measured as previously described35. VEGF levels were normalized to total protein from cell lysates using the BCA Protein Assay (Pierce, Rockford, IL). Fold values were generated by normalizing to the vehicle control.

Statistical analysis

For CNV and gene expression comparisons between cell lines, Student’s unpaired t-test was performed. For cell culture, each biological N was generated by an experiment on a unique passage day. Thus, Student’s paired t-test (two tailed) was performed to compare two groups. For multiple comparisons, Repeated Measures ANOVA was performed using Dunnett’s multiple comparison post-test against the vehicle control.


Propranolol inhibits CNV

In order to determine if β-adrenergic signaling plays a role in AMD, we tested propranolol in the in vivo laser-induced CNV model. Briefly, mice were anesthetized and treated with focal laser burns, which rupture Bruch’s membrane and induce CNV. Mice were treated with propranolol or citrate vehicle control for 14 days and assessed for CNV. We used intraperitoneal drug delivery because prior studies demonstrated positive results with this method32,33. We found that propranolol reduced the average CNV area by 2-fold (Fig. 1).

Figure 1
Propranolol suppresses CNV. A–B: Representative images of vehicle- and propranolol-treated choroidal-sclera flat mounts stained with ICAM-2. C: Quantitative analysis of vehicle (veh)- and propranolol-treated eyes. Propranolol reduced CNV by 50% ...

β-adrenoreceptors stimulate VEGF production in ChEC and RPE cells

We next sought to investigate the mechanism by which propranolol inhibits CNV. As discussed earlier, the choroidal endothelium and RPE have been consistently identified as key sources of VEGF production in histopathological studies of AMD. We thus began our in vitro analysis by assessing the levels of VEGF and β-adrenergic receptors in primary mouse ChEC and RPE cells. We found that ChEC and RPE cells express Vegf and the β2-adrenergic receptor at equal mRNA levels (Fig. 2). However, ChEC displayed significantly less β1- and β3-adrenoreceptor mRNA compared with RPE cells (Fig. 2B & 2D).

Figure 2
Quantitative PCR assessment of VEGF (A) and all three β-adrenoreceptors (B–D) in ChEC and RPE cells. Data are normalized to RpL 13A housekeeping gene expression (** p<0.01, *** p<0.001).

Since primary ChEC and RPE cells express VEGF and all three β-adrenoreceptors, these cells are a good in vitro model to investigate the role of β-adrenergic signaling in VEGF production. To test this hypothesis, we incubated ChEC and RPE cells with norepinephrine, a naturally produced neurotransmitter and hormone that stimulates α- and β-adrenergic receptors. We found that norepinephrine increased Vegf mRNA production by 4-fold in ChEC and RPE cells (Fig. 3A & 3C). In conditioned medium from these cells, norepinephrine incubation augmented VEGF secretion by 1.6- and 1.2-fold in RPE and ChEC cells, respectively (Fig. 3B & 3D).

Figure 3
Norepinephrine stimulates VEGF. A,C: RPE (N=6) and ChECs (N=7) were treated for 2 hours with vehicle or 10 μM norepinephrine (NE). B,D: VEGF secretion after 24 hours of treatment (N=6 for both, * p<0.05, ** p<0.01).

We next sought to inhibit the above effect with propranolol to replicate our CNV model in vitro and confirm that this effect is driven by β-adrenoreceptors. Propranolol completely inhibited norepinephrine-stimulated Vegf mRNA production in ChEC and RPE cells (Fig. 4). Furthermore, propranolol only prevented Vegf mRNA production in the presence of norepinephrine and had no effect on baseline Vegf mRNA levels.

Figure 4
Propranolol prevents norepinephrine-stimulated VEGF mRNA expression. RPE (A) and ChECs (B) were pre-incubated with 1 μM propranolol for 30 minutes followed by incubation with 10 μM norepinephrine for 2 hours (N=5 for both, *** p<0.001). ...

The β2-adrenoreceptor drives VEGF production

Since propranolol is a non-selective β-adrenergic receptor blocker, we next investigated which β-adrenoreceptor drives VEGF production. Prior to norepinephrine stimulation, we pre- incubated ChEC and RPE cells with selective β-adrenoreceptor antagonists: CGP 20712 (β1-adrenoreceptor), ICI 118,551 (β2-adrenoreceptor), and SR 59230A (β3-adrenoreceptor). We found that only the β2-adrenoreceptor antagonist was able to prevent norepinephrine-stimulated Vegf mRNA production (Fig. 5A & 5B). To confirm this result, we stimulated ChEC and RPE cells with selective β-adrenoreceptor agonists: xamoterol (β1-adrenoreceptor), formoterol (β2-adrenoreceptor), and BRL 37344 (β3-adrenoreceptor). Only the β2-selective agonist formoterol significantly increased Vegf mRNA production (Fig. 5C & 5D). Interestingly, treatment with the β3-adrenoreceptor agonist also trended toward a small positive effect on Vegf mRNA production (Fig. 5C & 5D).

Figure 5
β2-Adrenoreceptors drive VEGF. A–B: Cells were pre-incubated with 1 μM β1 or 100 nM β2 and β3 antagonists (N=4 for both). C–D: RPE (N=3) and ChECs (N=5) were incubated with 100 nM β1 and ...


Here we demonstrated that β-adrenoreceptor antagonism was effective to diminish CNV in the laser-induced mouse model. Furthermore, we showed that norepinephrine stimulates VEGF mRNA production and secretion via the β2-adrenergic receptor in primary ChEC and RPE cells. These results suggest that β2-adrenoreceptor blockers could be effective anti-VEGF therapeutics in CNV-driven diseases like exudative AMD, traumatic choroidal rupture, myopic CNV, and ocular histoplasmosis.

The use of β-adrenergic antagonism to suppress VEGF production and neovascularization has been previously shown in rodent models of retinopathy of prematurity. In the rat, topical timolol (a β-adrenergic receptor antagonist with highest affinity for the β2-adrenoreceptor36) diminishes retinal neovascularization during OIR37. More recently, the Bagnoli group showed that propranolol32 and a selective β2-adrenoreceptor blocker33 can both attenuate retinal neovascularization during OIR in mice by decreasing VEGF production. However, another group failed to demonstrate that propranolol could prevent retinal neovascularization in OIR mice38. Although Ristori et al hypothesized that the β3-adrenoreceptor stimulated VEGF expression because the β3-adrenergic receptor was up-regulated in OIR mice32, Martini et al conclusively demonstrated that the β2-adrenoreceptor modulates this effect via receptor-specific antagonism33. Although initially counter-intuitive, Dal Monte et al showed that chronic isoproterenol (a β1 and β2 adrenoreceptor agonist) treatment attenuates retinal neovascularization in OIR mice. This occurs by agonist-induced desensitization of the β2-adrenoreceptor39. Our results agree with the findings of Martini and Dal Monte et al, that the β2-adrenoreceptor is key in regulating VEGF expression. However, we do see a trend toward increased VEGF mRNA production with β3-adrenoreceptor agonism (Fig. 5), similar to the Ristori, et al. hypothesis. There may be a minor biological role for the β3-adrenoreceptor in VEGF production or we are simply seeing off-target effects because the pharmacological modulators of β2- and β3-adrenoreceptors have some overlap with each other. In summary, our data agree with prior reports, which demonstrate a role for β2-adrenoreceptor driven VEGF expression in OIR mice, and extend these results to the laser-induced CNV model.

There are several published reports, examining models of reduced ocular adrenergic signaling, but the results are conflicting. Chronic loss of adrenergic signaling in rats via surgical sympathectomy40 or propranolol41 treatment increases choroidal and retinal vascularity. Contrary to our findings, these results suggest that β-adrenergic signaling is anti-angiogenic. On the other hand, there are several reports that agree with our findings, showing that β-adrenergic signaling is pro-angiogenic. First, β3-adrenoreceptor agonism stimulates elongation, migration, and proliferation of human retinal42 and choroidal43 EC. In addition, surgical sympathectomy in rats decreases VEGF levels44, while isoproterenol treatment in human ChEC increases VEGF expression45. These studies demonstrate that β-adrenergic receptor signaling is pro-angiogenic and drives VEGF expression, in agreement with our results.

In addition, surgical sympathectomy in rats46, Dbh null mice (which cannot synthesize norepinephrine)47, and mice null for β1-adrenoreceptors48 display degenerate capillaries, pericyte loss, and increased basement membrane thickness, which are all hallmarks of non-proliferative diabetic retinopathy. In agreement, β1-adrenergic agonism reduces human retinal EC apoptosis49,50. These results suggest that loss of β1-adrenergic signaling can mimic early diabetic retinopathy. Our results identify the β2-adrenoreceptor as a driver of VEGF expression and specific therapeutic antagonism of the β2 adrenoreceptor should avoid the deleterious effects of β1-adrenergic blockade.

Despite the wealth of knowledge about VEGF and its expression, the specific driver of VEGF expression in exudative AMD remains unknown. In proliferative diabetic retinopathy and central retinal vessel occlusions, VEGF expression is driven by hypoxia51. However, the choroid provides more blood flow than is necessary and the role of hypoxia in AMD is unclear. Alternative hypotheses for drivers of VEGF expression in AMD include oxidative stress52, insulin-like growth factor-153, inflammatory cytokines7, transforming growth factor- β54, age55, and contact with choroidal endothelium55. Our results suggest that adrenergic signaling could also contribute to VEGF expression in CNV.

A potential negative consequence of anti-VEGF therapy is the inhibition of RPE-derived VEGF for normal visual function. Complete loss of RPE-derived VEGF expression causes absence of choriocapillaris development and poor vision56. Loss of RPE-derived soluble VEGF leads to choriocapillaris atrophy, RPE and Bruch’s membrane abnormalities, and photoreceptor death57. Importantly, β-adrenergic antagonism does not suppress baseline VEGF expression in RPE cells (Fig. 4), suggesting that therapeutic β2-adrenergic blockade would not have these complications.

Our studies have several important limitations and considerations for clinical translation. First, the laser-induced CNV model more closely approximates post-traumatic CNV after choroidal rupture and post-inflammatory CNV in the context of diseases like histoplasmosis than it does exudative AMD. Second, our studies used systemic, intraperitoneal drug delivery. Prior studies show that systemic propranolol affects retinal phenotypes, including the electroretinogram58 and NV32,33, demonstrating that systemic propranolol penetrates to the posterior eye. Additionally, pharmacokinetic studies find that highly lipophilic β-adrenoreceptor blockers, like propranolol, are most highly concentrated in the RPE and choroid after either intravitreal or subconjunctival injection59,60. Therefore, local propranolol could be highly effective for CNV due to its lipophilic nature; we will assess this hypothesis in future studies. Finally, our studies used primary mouse RPE cells after passaging. We recognize that primary RPE cells lose some characteristic phenotypes with passaging, but our cells maintain bestrophin and RPE65 expression at up to 20 passages. We will assess this limitation in future studies using fresh human fetal RPE cells.

In conclusion, we have identified β2-adrenergic signaling as a potential driver of RPE and ChEC VEGF expression in CNV. Future studies will extend these results to human models and expand the mechanism beyond the β2-adrenoreceptor.


This work was supported by grants EY016995, EY021357 (NS), and P30-EY16665, from the National Institutes of Health and an unrestricted departmental award from Research to Prevent Blindness. JAL was supported by the Medical Scientist Training Program. NS is a recipient of a Research Award from American Diabetes Association, 1-10-BS-160 and Retina Research Foundation. CMS is supported by a grant from American Heart Association, 0950057G. We thank Elizabeth A. Scheef for her expertise and help with cell culture studies. We thank SunYoung Park for her assistance with VEGF ELISA assays. NS had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.


1. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. The Lancet. 2012;379(9827):1728–1738. [PubMed]
2. Lopez PF, Grossniklaus HE, Lambert HM, et al. Pathologic features of surgically excised subretinal neovascular membranes in age-related macular degeneration. American Journal of Ophthalmology. 1991;112(6):647–656. [PubMed]
3. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. American Journal of Ophthalmology. 1992;114(4):464–472. [PubMed]
4. Thomas JW, Grossniklaus HE, Lambert HM, Aaberg TM, L’Hernault N. Ultrastructural features of surgically excised idiopathic subfoveal neovascular membranes. Retina (Philadelphia, Pa ) 1993;13(2):93–98. [PubMed]
5. Lopez PF, Lambert HM, Grossniklaus HE, Sternberg P. Well-defined subfoveal choroidal neovascular membranes in age-related macular degeneration. Ophthalmology. 1993;100(3):415– 422. [PubMed]
6. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Investigative Ophthalmology & Visual Science. 1996;37(5):855–868. [PubMed]
7. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Investigative Ophthalmology & Visual Science. 1999;40(9):1891–1898. [PubMed]
8. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis. 2002;8(8):119– 126. [PubMed]
9. Amin R, Puklin JE, Frank RN. Growth factor localization in choroidal neovascular membranes of age-related macular degeneration. Investigative Ophthalmology & Visual Science. 1994;35(8):3178–3188. [PubMed]
10. Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, de Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. British Journal of Ophthalmology. 1997;81(2):154–162. [PMC free article] [PubMed]
11. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of vascular endothelial growth factor in human retina and choroid. Archives of Ophthalmology. 1996;114(8):971. [PubMed]
12. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Investigative Ophthalmology & Visual Science. 1996;37(9):1929–1934. [PubMed]
13. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Experimental Eye Research. 2006;82(1):99–110. [PubMed]
14. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246(4935):1306. [PubMed]
15. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983–985. [PubMed]
16. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res. 1999;18(3):203–213. [PubMed]
17. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Investigative Ophthalmology & Visual Science. 2000;41(10):3158– 3164. [PubMed]
18. Tobe T, Okamoto N, Vinores MA, et al. Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors. Investigative Ophthalmology & Visual Science. 1998;39(1):180–188. [PubMed]
19. Schwesinger C, Yee C, Rohan RM, et al. Intrachoroidal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium. Am J Pathol. 2001;158(3):1161–1172. [PubMed]
20. Spilsbury K, Garrett KL, Shen WY, Constable IJ, Rakoczy PE. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000;157(1):135–144. [PubMed]
21. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432–1444. [PubMed]
22. Rosenfeld P, Brown D, Heier J, Boyer D. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006 [PubMed]
23. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo J-B, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358(24):2649–2651. [PubMed]
24. Haider KM, Plager DA, Neely DE, Eikenberry J, Haggstrom A. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. Journal of AAPOS. 2010;14(3):251– 256. [PubMed]
25. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939–944. [PubMed]
26. Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514–4521. [PubMed]
27. Fredriksson JM, Lindquist JM, Bronnikov GE, Nedergaard J. Norepinephrine induces vascular endothelial growth factor gene expression in brown adipocytes through a beta - adrenoreceptor/cAMP/protein kinase A pathway involving Src but independently of Erk1/2. J Biol Chem. 2000;275(18):13802–13811. [PubMed]
28. Hajighasemi F, Hajighasemi S. Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro. Iran Biomed J. 2009;13(4):223–228. [PubMed]
29. SEYA Y, FUKUDA T, ISOBE K, KAWAKAMI Y, TAKEKOSHI K. Effect of norepinephrine on RhoA, MAP kinase, proliferation and VEGF expression in human umbilical vein endothelial cells. European Journal of Pharmacology. 2006;553(1–3):54–60. [PubMed]
30. Annabi B, Lachambre M-P, Plouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacological Research. 2009;60(5):438–445. [PubMed]
31. Lamy S, Lachambre M-P, Lord-Dufour S, Béliveau R. Propranolol suppresses angiogenesis in vitro: Inhibition of proliferation, migration, and differentiation of endothelial cells. Vascular Pharmacology. 2010;53(5–6):200–208. [PubMed]
32. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Investigative Ophthalmology & Visual Science. 2011;52(1):155–170. [PubMed]
33. Martini D, Monte MD, Ristori C, et al. Antiangiogenic effects of β2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. Journal of Neurochemistry. 2011;119(6):1317–1329. [PubMed]
34. Wang S, Sorenson CM, Sheibani N. Lack of Thrombospondin 1 and Exacerbation of Choroidal Neovascularization. Archives of Ophthalmology. 2012 [PMC free article] [PubMed]
35. Park S, DiMaio TA, Scheef EA, Sorenson CM, Sheibani N. PECAM-1 regulates proangiogenic properties of endothelial cells through modulation of cell-cell and cell-matrix interactions. AJP: Cell Physiology. 2010;299(6):C1468–C1484. [PubMed]
36. Baker JG. The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol. 2005;144(3):317–322. [PMC free article] [PubMed]
37. Ricci B, Ricci F, Maggiano N. Oxygen-induced retinopathy in the newborn rat: morphological and immunohistological findings in animals treated with topical timolol maleate. Ophthalmologica. 2000;214(2):136–139. [PubMed]
38. Chen J, Joyal J, Hatton C, Juan A. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Ophthalmology & Visual. 2012 [PMC free article] [PubMed]
39. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P. Beta-Adrenoreceptor Agonism Influences Retinal Responses to Hypoxia in a Model of Retinopathy of Prematurity. Investigative Ophthalmology & Visual Science. 2012;53(4):2181–2192. [PubMed]
40. Steinle JJ, Pierce JD, Clancy RL, Smith GP. Increased Ocular Blood Vessel Numbers and Sizes Following Chronic Sympathectomy in Rat. Experimental Eye Research. 2002;74(6):761– 768. [PubMed]
41. Steinle JJ, Smith PG. Role of adrenergic receptors in vascular remodelling of the rat choroid. Br J Pharmacol. 2002;136(5):730–734. [PMC free article] [PubMed]
42. Steinle JJ. beta3-Adrenergic Receptors Regulate Retinal Endothelial Cell Migration and Proliferation. Journal of Biological Chemistry. 2003;278(23):20681–20686. [PubMed]
43. STEINLE J, ZAMORA D, ROSENBAUM J, GRANGER H. β-Adrenergic receptors mediate choroidal endothelial cell invasion, proliferation, and cell elongation. Experimental Eye Research. 2005;80(1):83–91. [PubMed]
44. Wiley LA, Berkowitz BA, Steinle JJ. Superior cervical ganglionectomy induces changes in growth factor expression in the rat retina. Investigative Ophthalmology & Visual Science. 2006;47(1):439–443. [PubMed]
45. Steinle JJ, Cappocia FC, Jr, Jiang Y. Beta-adrenergic receptor regulation of growth factor protein levels in human choroidal endothelial cells. Growth Factors. 2008;26(6):325–330. [PubMed]
46. Wiley LA. Sympathetic Innervation Regulates Basement Membrane Thickening and Pericyte Number in Rat Retina. Investigative Ophthalmology & Visual Science. 2005;46(2):744–748. [PubMed]
47. Steinle JJ, Kern TS, Thomas SA, McFadyen-Ketchum LS, Smith CP. Increased basement membrane thickness, pericyte ghosts, and loss of retinal thickness and cells in dopamine beta hydroxylase knockout mice. Experimental Eye Research. 2009;88(6):1014–1019. [PubMed]
48. Panjala SR, Jiang Y, Kern TS, Thomas SA, Steinle JJ. Increased tumor necrosis factor-α, cleaved caspase 3 levels and insulin receptor substrate-1 phosphorylation in the β-adrenergic receptor knockout mouse. Mol Vis. 2011;17:1822–1828. [PMC free article] [PubMed]
49. Williams KP, Steinle JJ. Maintenance of beta-adrenergic receptor signaling can reduce fas signaling in human retinal endothelial cells. Experimental Eye Research. 2009;89(4):448–455. [PubMed]
50. Panjala SR, Steinle JJ. Insulin and β-adrenergic Receptors Inhibit Retinal Endothelial Cell Apoptosis Through Independent Pathways. Neurochem Res. 2010;36(4):604–612. [PubMed]
51. Shima D, Adamis A, Ferrara N, et al. Hypoxic induction of endothelial cell growth factors in retinal cells: identification and characterization of vascular endothelial growth factor (VEGF) as the mitogen. Molecular Medicine. 1995;1(2):182. [PMC free article] [PubMed]
52. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest. 1996;98(7):1667–1675. [PMC free article] [PubMed]
53. Punglia RS, Lu M, Hsu J, et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes. 1997;46(10):1619–1626. [PubMed]
54. Bian ZM, Elner SG, Elner VM. Regulation of VEGF mRNA expression and protein secretion by TGF-β2 in human retinal pigment epithelial cells. Experimental Eye Research. 2007;84(5):812–822. [PMC free article] [PubMed]
55. Wang H, Geisen P, Wittchen ES, et al. The Role of RPE Cell-Associated VEGF189 in Choroidal Endothelial Cell Transmigration across the RPE. Investigative Ophthalmology & Visual Science. 2011;52(1):570–578. [PMC free article] [PubMed]
56. Marneros AG, Fan J, Yokoyama Y, et al. Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol. 2005;167(5):1451–1459. [PubMed]
57. Saint-Geniez M, Kurihara T, Sekiyama E, Maldonado AE, D’Amore PA. An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris. Proc Natl Acad Sci US A. 2009;106(44):18751–18756. [PubMed]
58. Jiang Y, Steinle JJ. Systemic propranolol reduces b-wave amplitude in the ERG and increases IGF-1 receptor phosphorylation in rat retina. Investigative Ophthalmology & Visual Science. 2010;51(5):2730–2735. [PMC free article] [PubMed]
59. Mains J, Tan LE, Wilson C, Urquhart A. A pharmacokinetic study of a combination of beta adrenoreceptor antagonists – In the isolated perfused ovine eye. European Journal of Pharmaceutics and Biopharmaceutics. 2012;80(2):393–401. [PubMed]
60. Kadam RS, Kompella UB. Influence of Lipophilicity on Drug Partitioning into Sclera, Choroid-Retinal Pigment Epithelium, Retina, Trabecular Meshwork, and Optic Nerve. Journal of Pharmacology and Experimental Therapeutics. 2010;332(3):1107–1120. [PubMed]